Published in Biochemistry on July 25, 2006
Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2. Cancer Res (2008) 2.04
Apatinib (YN968D1) reverses multidrug resistance by inhibiting the efflux function of multiple ATP-binding cassette transporters. Cancer Res (2010) 1.55
The "specific" P-glycoprotein inhibitor Tariquidar is also a substrate and an inhibitor for breast cancer resistance protein (BCRP/ABCG2). ACS Chem Neurosci (2010) 1.46
Sunitinib (Sutent, SU11248), a small-molecule receptor tyrosine kinase inhibitor, blocks function of the ATP-binding cassette (ABC) transporters P-glycoprotein (ABCB1) and ABCG2. Drug Metab Dispos (2008) 1.46
Sildenafil reverses ABCB1- and ABCG2-mediated chemotherapeutic drug resistance. Cancer Res (2011) 1.34
Structure and function of the human breast cancer resistance protein (BCRP/ABCG2). Curr Drug Metab (2010) 1.33
Human ABCG2: structure, function, and its role in multidrug resistance. Int J Biochem Mol Biol (2011) 1.21
Inhibition of P-glycoprotein (ABCB1)- and multidrug resistance-associated protein 1 (ABCC1)-mediated transport by the orally administered inhibitor, CBT-1((R)). Biochem Pharmacol (2007) 1.19
New inhibitors of ABCG2 identified by high-throughput screening. Mol Cancer Ther (2007) 1.18
Role of the breast cancer resistance protein (BCRP/ABCG2) in drug transport--an update. AAPS J (2014) 1.17
Evidence for dual mode of action of a thiosemicarbazone, NSC73306: a potent substrate of the multidrug resistance linked ABCG2 transporter. Mol Cancer Ther (2007) 1.13
The ABCG family of membrane-associated transporters: you don't have to be big to be mighty. Br J Pharmacol (2011) 1.13
Inhibiting the function of ABCB1 and ABCG2 by the EGFR tyrosine kinase inhibitor AG1478. Biochem Pharmacol (2008) 1.12
Both P-gp and MRP2 mediate transport of Lopinavir, a protease inhibitor. Int J Pharm (2007) 1.10
The challenge of exploiting ABCG2 in the clinic. Curr Pharm Biotechnol (2011) 1.06
Botryllamides: natural product inhibitors of ABCG2. ACS Chem Biol (2009) 1.05
Use of baculovirus BacMam vectors for expression of ABC drug transporters in mammalian cells. Drug Metab Dispos (2011) 1.05
Curcumin inhibits the activity of ABCG2/BCRP1, a multidrug resistance-linked ABC drug transporter in mice. Pharm Res (2008) 1.03
The novel BCR-ABL and FLT3 inhibitor ponatinib is a potent inhibitor of the MDR-associated ATP-binding cassette transporter ABCG2. Mol Cancer Ther (2012) 1.03
ABCG2 is related with the grade of glioma and resistance to mitoxantone, a chemotherapeutic drug for glioma. J Cancer Res Clin Oncol (2009) 1.01
Icotinib antagonizes ABCG2-mediated multidrug resistance, but not the pemetrexed resistance mediated by thymidylate synthase and ABCG2. Oncotarget (2014) 0.91
Identification of compounds that correlate with ABCG2 transporter function in the National Cancer Institute Anticancer Drug Screen. Mol Pharmacol (2009) 0.84
The Pim kinase inhibitor SGI-1776 decreases cell surface expression of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and drug transport by Pim-1-dependent and -independent mechanisms. Biochem Pharmacol (2012) 0.84
The naphthoquinones, vitamin K3 and its structural analogue plumbagin, are substrates of the multidrug resistance linked ATP binding cassette drug transporter ABCG2. Mol Cancer Ther (2007) 0.84
Association of the ABCG2 C421A polymorphism with prostate cancer risk and survival. BJU Int (2008) 0.84
Rational mutational analysis of a multidrug MFS transporter CaMdr1p of Candida albicans by employing a membrane environment based computational approach. PLoS Comput Biol (2009) 0.84
Why we should be vigilant: drug cytotoxicity observed with in vitro transporter inhibition studies. Biochem Pharmacol (2010) 0.83
Becatecarin (rebeccamycin analog, NSC 655649) is a transport substrate and induces expression of the ATP-binding cassette transporter, ABCG2, in lung carcinoma cells. Cancer Chemother Pharmacol (2009) 0.82
The Inhibitor Ko143 Is Not Specific for ABCG2. J Pharmacol Exp Ther (2015) 0.82
Effect of ceritinib (LDK378) on enhancement of chemotherapeutic agents in ABCB1 and ABCG2 overexpressing cells in vitro and in vivo. Oncotarget (2015) 0.81
The FLT3 inhibitor quizartinib inhibits ABCG2 at pharmacologically relevant concentrations, with implications for both chemosensitization and adverse drug interactions. PLoS One (2013) 0.80
ARRY-334543 reverses multidrug resistance by antagonizing the activity of ATP-binding cassette subfamily G member 2. J Cell Biochem (2014) 0.79
Pharmacophore modeling of nilotinib as an inhibitor of ATP-binding cassette drug transporters and BCR-ABL kinase using a three-dimensional quantitative structure-activity relationship approach. Mol Pharm (2014) 0.79
In vitro and in vivo modulation of ABCG2 by functionalized aurones and structurally related analogs. Biochem Pharmacol (2011) 0.78
A combination of curcumin with either gramicidin or ouabain selectively kills cells that express the multidrug resistance-linked ABCG2 transporter. J Biol Chem (2014) 0.77
Tariquidar Is an Inhibitor and Not a Substrate of Human and Mouse P-glycoprotein. Drug Metab Dispos (2015) 0.75
Tyrphostin RG14620 selectively reverses ABCG2-mediated multidrug resistance in cancer cell lines. Cancer Lett (2017) 0.75
Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer (2002) 15.72
A "silent" polymorphism in the MDR1 gene changes substrate specificity. Science (2006) 15.18
Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms. Clin Cancer Res (2002) 4.90
Brca1 breast tumors contain distinct CD44+/CD24- and CD133+ cells with cancer stem cell characteristics. Breast Cancer Res (2008) 3.98
The role of ABC transporters in clinical practice. Oncologist (2003) 3.21
Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma. J Clin Oncol (2009) 3.13
Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma. Blood (2011) 2.64
Cardiac studies in patients treated with depsipeptide, FK228, in a phase II trial for T-cell lymphoma. Clin Cancer Res (2006) 2.61
Tumor regression and growth rates determined in five intramural NCI prostate cancer trials: the growth rate constant as an indicator of therapeutic efficacy. Clin Cancer Res (2010) 2.45
Peripheral CB1 cannabinoid receptor blockade improves cardiometabolic risk in mouse models of obesity. J Clin Invest (2010) 2.32
ABCG2: determining its relevance in clinical drug resistance. Cancer Metastasis Rev (2007) 2.31
Sunitinib does not accelerate tumor growth in patients with metastatic renal cell carcinoma. Cell Rep (2013) 2.24
Erlotinib (Tarceva, OSI-774) antagonizes ATP-binding cassette subfamily B member 1 and ATP-binding cassette subfamily G member 2-mediated drug resistance. Cancer Res (2007) 2.15
Tariquidar (XR9576): a P-glycoprotein drug efflux pump inhibitor. Expert Rev Anticancer Ther (2007) 2.11
Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2. Cancer Res (2008) 2.04
Redefining the relevance of established cancer cell lines to the study of mechanisms of clinical anti-cancer drug resistance. Proc Natl Acad Sci U S A (2011) 1.97
ABCG2: a perspective. Adv Drug Deliv Rev (2008) 1.97
Silent polymorphisms speak: how they affect pharmacogenomics and the treatment of cancer. Cancer Res (2007) 1.91
Prolonged drug selection of breast cancer cells and enrichment of cancer stem cell characteristics. J Natl Cancer Inst (2010) 1.89
Histone deacetylase inhibitors all induce p21 but differentially cause tubulin acetylation, mitotic arrest, and cytotoxicity. Mol Cancer Ther (2002) 1.88
Tumor growth rates derived from data for patients in a clinical trial correlate strongly with patient survival: a novel strategy for evaluation of clinical trial data. Oncologist (2008) 1.85
Evaluation of current methods used to analyze the expression profiles of ATP-binding cassette transporters yields an improved drug-discovery database. Mol Cancer Ther (2009) 1.83
MS-27-275, an inhibitor of histone deacetylase, has marked in vitro and in vivo antitumor activity against pediatric solid tumors. Cancer Res (2002) 1.82
Pheophorbide a is a specific probe for ABCG2 function and inhibition. Cancer Res (2004) 1.82
Synonymous mutations and ribosome stalling can lead to altered folding pathways and distinct minima. J Mol Biol (2008) 1.80
ABCG2-mediated transport of photosensitizers: potential impact on photodynamic therapy. Cancer Biol Ther (2005) 1.79
ABCG2: structure, function and role in drug response. Expert Opin Drug Metab Toxicol (2008) 1.65
Selective toxicity of NSC73306 in MDR1-positive cells as a new strategy to circumvent multidrug resistance in cancer. Cancer Res (2006) 1.64
Transport of methotrexate, methotrexate polyglutamates, and 17beta-estradiol 17-(beta-D-glucuronide) by ABCG2: effects of acquired mutations at R482 on methotrexate transport. Cancer Res (2003) 1.62
Silent (synonymous) SNPs: should we care about them? Methods Mol Biol (2009) 1.61
Regulation of ABCG2 expression at the 3' untranslated region of its mRNA through modulation of transcript stability and protein translation by a putative microRNA in the S1 colon cancer cell line. Mol Cell Biol (2008) 1.58
Vascular targeting and antiangiogenesis agents induce drug resistance effector GRP78 within the tumor microenvironment. Cancer Res (2005) 1.55
Apatinib (YN968D1) reverses multidrug resistance by inhibiting the efflux function of multiple ATP-binding cassette transporters. Cancer Res (2010) 1.55
Overexpression of wild-type breast cancer resistance protein mediates methotrexate resistance. Cancer Res (2002) 1.50
Potential pitfalls of crossover and thoughts on iniparib in triple-negative breast cancer. J Natl Cancer Inst (2011) 1.50
VAMP2-dependent exocytosis regulates plasma membrane insertion of TRPC3 channels and contributes to agonist-stimulated Ca2+ influx. Mol Cell (2004) 1.49
Association of variant ABCG2 and the pharmacokinetics of epidermal growth factor receptor tyrosine kinase inhibitors in cancer patients. Cancer Biol Ther (2007) 1.47
The "specific" P-glycoprotein inhibitor Tariquidar is also a substrate and an inhibitor for breast cancer resistance protein (BCRP/ABCG2). ACS Chem Neurosci (2010) 1.46
Reversal of ABC drug transporter-mediated multidrug resistance in cancer cells: evaluation of current strategies. Curr Mol Pharmacol (2008) 1.46
Sunitinib (Sutent, SU11248), a small-molecule receptor tyrosine kinase inhibitor, blocks function of the ATP-binding cassette (ABC) transporters P-glycoprotein (ABCB1) and ABCG2. Drug Metab Dispos (2008) 1.46
EZH2 Mediates epigenetic silencing of neuroblastoma suppressor genes CASZ1, CLU, RUNX3, and NGFR. Cancer Res (2011) 1.46
Cardiac involvement with lymphoma: a review of the literature. Clin Lymphoma Myeloma (2008) 1.43
Comparison of ATP-binding cassette transporter interactions with the tyrosine kinase inhibitors imatinib, nilotinib, and dasatinib. Drug Metab Dispos (2010) 1.41
Functional characterization of Candida albicans ABC transporter Cdr1p. Eukaryot Cell (2003) 1.40
Epigenetic modifiers: basic understanding and clinical development. Clin Cancer Res (2009) 1.38
Catalytic cycle of ATP hydrolysis by P-glycoprotein: evidence for formation of the E.S reaction intermediate with ATP-gamma-S, a nonhydrolyzable analogue of ATP. Biochemistry (2007) 1.35
Modulation of P-glycoprotein expression and function by curcumin in multidrug-resistant human KB cells. Biochem Pharmacol (2002) 1.35
Drug resistance: still a daunting challenge to the successful treatment of AML. Drug Resist Updat (2012) 1.35
Sildenafil reverses ABCB1- and ABCG2-mediated chemotherapeutic drug resistance. Cancer Res (2011) 1.34
Histone modifications at the ABCG2 promoter following treatment with histone deacetylase inhibitor mirror those in multidrug-resistant cells. Mol Cancer Res (2008) 1.34
Romidepsin: a new therapy for cutaneous T-cell lymphoma and a potential therapy for solid tumors. Expert Rev Anticancer Ther (2010) 1.34
Flavonoid structure-activity studies identify 6-prenylchrysin and tectochrysin as potent and specific inhibitors of breast cancer resistance protein ABCG2. Cancer Res (2005) 1.33
Human ABCB6 localizes to both the outer mitochondrial membrane and the plasma membrane. Biochemistry (2007) 1.33
Development of inhibitors of ATP-binding cassette drug transporters: present status and challenges. Expert Opin Drug Metab Toxicol (2008) 1.32
Single nucleotide polymorphisms modify the transporter activity of ABCG2. Cancer Chemother Pharmacol (2005) 1.30
Mutational analysis of ABCG2: role of the GXXXG motif. Biochemistry (2004) 1.29
Side population analysis using a violet-excited cell-permeable DNA binding dye. Stem Cells (2006) 1.29
Inhibitors of histone deacetylases alter kinetochore assembly by disrupting pericentromeric heterochromatin. Cell Cycle (2005) 1.29
About a switch: how P-glycoprotein (ABCB1) harnesses the energy of ATP binding and hydrolysis to do mechanical work. Mol Cancer Ther (2007) 1.27
A high-throughput cell-based assay for inhibitors of ABCG2 activity. J Biomol Screen (2006) 1.26
Aberrant promoter methylation of the ABCG2 gene in renal carcinoma. Mol Cell Biol (2006) 1.26
Targeting MDR in breast and lung cancer: discriminating its potential importance from the failure of drug resistance reversal studies. Drug Resist Updat (2012) 1.23
A Serial Analysis of Gene Expression (SAGE) database analysis of chemosensitivity: comparing solid tumors with cell lines and comparing solid tumors from different tissue origins. Cancer Res (2004) 1.23
Relationship of EGFR mutations, expression, amplification, and polymorphisms to epidermal growth factor receptor inhibitors in the NCI60 cell lines. Clin Cancer Res (2007) 1.20
Importance of the conserved Walker B glutamate residues, 556 and 1201, for the completion of the catalytic cycle of ATP hydrolysis by human P-glycoprotein (ABCB1). Biochemistry (2002) 1.20
Inhibition of P-glycoprotein (ABCB1)- and multidrug resistance-associated protein 1 (ABCC1)-mediated transport by the orally administered inhibitor, CBT-1((R)). Biochem Pharmacol (2007) 1.19
Interindividual variability in hepatic organic anion-transporting polypeptides and P-glycoprotein (ABCB1) protein expression: quantification by liquid chromatography tandem mass spectroscopy and influence of genotype, age, and sex. Drug Metab Dispos (2013) 1.18
The controversial role of ABC transporters in clinical oncology. Essays Biochem (2011) 1.18
ABC drug transporters as molecular targets for the prevention of multidrug resistance and drug-drug interactions. Curr Drug Deliv (2007) 1.18
New inhibitors of ABCG2 identified by high-throughput screening. Mol Cancer Ther (2007) 1.18
Increased MDR1 expression in normal and malignant peripheral blood mononuclear cells obtained from patients receiving depsipeptide (FR901228, FK228, NSC630176). Clin Cancer Res (2006) 1.18
Population pharmacokinetics of romidepsin in patients with cutaneous T-cell lymphoma and relapsed peripheral T-cell lymphoma. Clin Cancer Res (2009) 1.17
Modulation of function of three ABC drug transporters, P-glycoprotein (ABCB1), mitoxantrone resistance protein (ABCG2) and multidrug resistance protein 1 (ABCC1) by tetrahydrocurcumin, a major metabolite of curcumin. Mol Cell Biochem (2006) 1.16
A phase I study of the P-glycoprotein antagonist tariquidar in combination with vinorelbine. Clin Cancer Res (2009) 1.15